# Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Source: https://onco.cc/trials/nct06631079/  
OnCo record `nct06631079` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of NECVAX-NEO1 in advanced solid tumours, run by NEC Bio B.V, active and no longer recruiting.

## Summary

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT06631079 by NEC Bio B.V, with 20 participants enrolled, started 2024-10-07 and due to reach its primary completion in 2026-07-31. Interventions recorded: NECVAX-NEO1.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06631079
- Phase: 1/2
- Setting: An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors
- Sponsor: NEC Bio B.V
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06631079: https://clinicaltrials.gov/study/NCT06631079

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06631079.json